TURBT, or transurethral resection of bladder tumor, is a common, minimally invasive outpatient procedure used to diagnose, stage, and treat bladder cancer.

Transurethral resection of bladder tumor (TURBT, also known as transurethral resection, or TUR) is the most common surgery for bladder cancer that’s in early stages.

Management The patient underwent open bladder resection with total excision of the neoplasm and was administered adjuvant chemotherapy consisting of irinotecan and cetuximab.

The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication ...

The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's drug to treat a type of bladder cancer, providing an alternative treatment as opposed to traditional surgical procedures. U.S ...

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

TURBT was associated with persistent sexual dysfunction in men, pointing to the importance of incorporating sexual health into postoperative evaluation.

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral resection of bladder tumor (TURBT) was associated with a favorable safety ...